INTRODUCTION {#s1}
============

In colorectal cancer, the influence of the tumor microenvironment with its immune effectors for disease outcome is increasingly acknowledged \[[@R1]\]. The recent study demonstrating favorable survival following immune checkpoint blockade in metastatic disease from mismatch repair-deficient tumors with a high density of immunogenic neo-antigens will obviously be regarded as a landmark contribution to the concept of immune modulation in colorectal cancer \[[@R2]\].

As a result of systematic improvements that include multimodal therapy, primarily neoadjuvant chemoradiotherapy (CRT) followed by surgery, long-term local control is commonly achieved in locally advanced rectal cancer (LARC) \[[@R3]\]. The unrivalled efficacy of radiotherapy in treatment of local tumor manifestations is a reflection of a delivered radiation dose that is commonly at the limit of normal tissue tolerance, and the improved survival outcomes resulting from the increasingly complex multimodality programs are often at the price of significant toxicities \[[@R4]\]. In pelvic curative CRT, enteritis that clinically presents as severe diarrhea may be a major adverse effect \[[@R5], [@R6]\].

Moreover, following curatively intended combined-modality therapy in LARC, a substantial number of patients will proceed to metastatic disease as a result of distant organ establishment of tumor cells with clonogenic potential \[[@R7]\]. Keeping this in mind, intriguing preclinical and clinical findings have suggested that the inflammatory, pro-immunogenic response to radiation damage within the tumor microenvironment may exert systemic anti-tumor activity at manifestations outside the radiation target volume. This comprises the so-called abscopal effect caused by radiation-induced immunogenic tumor cell death with the resulting cross-priming, via presentation of tumor antigens by dendritic cells, of tumor-targeting T lymphocytes \[[@R8]-[@R13]\].

Hence, within the frame of a prospective study for LARC patients (mainly T3--4 cases) given an intensified neoadjuvant treatment schedule and with long-term follow-up to observe metastatic progression \[[@R14]\], we investigated whether circulating inflammatory factors may relate to treatment toxicity and survival outcome. Study patients received short-course induction neoadjuvant chemotherapy (NACT) followed by long-course CRT before final pelvic surgery \[[@R14]\]. We employed an antibody array technology to monitor approximately 500 circulating proteins in serial serum samples collected throughout the full neoadjuvant course as a real-time approach to tumor responses and the constitutional and acquired physiology of the patients. In the resulting data set, the soluble tumor necrosis factor (TNF) decoy receptor osteoprotegerin (OPG) presented the most marked response to the neoadjuvant therapy (Table [1](#T1){ref-type="table"}).

###### Significantly altered serum proteins during neoadjuvant therapy

  Post-NACT     Post-CRT   Evaluation                                                               
  ------------- ---------- ------------ ------ ------------- -------- -------- ------ ------------- --------
  ADIPOQ        1.15       ACVR1        1.10   IGFBP3        1.21     ADIPOQ   1.10   GRN           1.12
  ANG           1.21       ADIPOQ       1.10   IGFBP7        1.12     ANG      1.11   IGF2          1.21
  IGFBP2        1.15       ANG          1.21   IL1RAPL2      1.10     ANGPT2   1.16   IGFBP7        1.15
  IL6ST         1.12       BMPR1A       1.11   IL27          1.12     BDNF     1.11   IL1RAPL2      1.11
  NCAM1         1.12       CCL1         1.11   IL6ST         1.17     BMPR1A   1.18   IL22          1.12
  SAA1          1.15       CCL11        1.12   LBP           1.16     CCL11    1.14   IL6ST         1.12
  *TNFRSF11B*   *1.34*     CCL22        1.13   LEPR          1.11     CCR6     1.14   LIFR          1.12
                           CCR6         1.10   PLAU          1.12     CD14     1.13   MMP2          1.10
                           CD14         1.14   RARRES2       1.12     CSF1     1.19   NGFB          1.12
                           CSF1         1.22   RELT          1.11     CTF1     1.12   NTF4          1.13
                           EGFR         1.11   SAA1          1.27     CXCR1    1.19   RARRES2       1.23
                           ERBB2        1.20   SIGLEC5       1.14     CXCR5    1.11   SIGLEC9       1.12
                           FLT3LG       1.11   SIGLEC9       1.13     CXCR6    1.12   SLC2A2        1.19
                           GCG          1.13   SLC2A2        1.13     ERBB2    1.11   THBS4         1.12
                           GRN          1.16   TGFBR1        1.11     ERBB4    1.11   *TNFRSF11B*   *1.16*
                           IGF2         1.18   THBS4         1.10     FLT3LG   1.12                 
                           IGFBP2       1.15   *TNFRSF11B*   *1.65*                                 
  LCN2          0.65       CHRDL2       0.88   PDGFA         0.86     CHRDL2   0.86   PDGFA         0.88
  LTBP1         0.87       CXCL2        0.88   PDGFB         0.89     FGF13    0.84   S100A12       0.84
  MMP9          0.63       FGF13        0.83   PF4           0.85     LCN2     0.84   TMEFF2        0.89
                           LCN2         0.73   PPBP          0.83     MMP9     0.74                 
                           LTBP1        0.80   S100A12       0.85                                   
                           MMP9         0.68   THBS1         0.84                                   

Array values of the proteins were transformed to natural logarithms. The fold-change increase or decrease following induction neoadjuvant chemotherapy (post-NACT) and sequential chemoradiotherapy (post-CRT) and at evaluation of the neoadjuvant treatment, relative to baseline, is indicated on the right of each protein. Proteins are listed by their gene names (TNFRSF11B, in italic, corresponds to osteoprotegerin).

OPG (TNFRSF11B) is a glycoprotein expressed by several cell types, including dendritic cells and CD4-positive T lymphocytes, which binds the ligand of the receptor activator of nuclear factor-kappaB (RANK), RANKL \[[@R15]-[@R17]\]. The OPG/RANKL/RANK system is involved in a wide variety of biological processes and is essential for bone-resorbing osteoclast activity in bone remodeling \[[@R17]-[@R19]\]. In particular, RANKL-induced signaling is implicated in the antigen-specific interaction between dendritic cells and T lymphocytes, allowing the immune system to recognize and destroy abnormal cells with non-self antigens \[[@R19]\].

In this LARC study, systemic immunological markers and particularly the alterations in circulating levels of OPG during the neoadjuvant treatment course were correlated to progression-free survival (PFS) and treatment toxicity as prospectively assessed by Common Terminology Criteria for Adverse Events (CTCAE) scoring, a comprehensive grading system for adverse treatment effects \[[@R20]\]. This approach may provide insight into systemic anti-tumor immunity invoked by combined-modality radiotherapy in a patient population treated with curative intent but with a significant risk of metastatic disease as an adverse outcome.

RESULTS {#s2}
=======

Circulating proteins during the course of neoadjuvant therapy {#s2_1}
-------------------------------------------------------------

The high-density antibody array, covering approximately 500 different proteins that include cytokines, growth factors, and proteinases among others, was applied to analyze serial serum samples collected from 66 of the study patients at baseline, at completion of four weeks of induction NACT (post-NACT) and the sequential 5-week CRT course (post-CRT), and at evaluation of the neoadjuvant treatment four weeks later. Analysis of the array data set by Significance Analysis of Microarrays (SAM) revealed significant changes in levels of a number of serum proteins during the neoadjuvant treatment course (Table [1](#T1){ref-type="table"}) with OPG showing the strongest increase (mean fold-change from baseline of data transformed to natural logarithms) of 1.34 and 1.65, respectively, at the post-NACT and post-CRT sampling points.

Circulating OPG and markers of systemic inflammation {#s2_2}
----------------------------------------------------

Serum OPG was therefore assessed by a single-parameter immunoassay in samples collected at baseline, post-NACT, post-CRT, and evaluation. Increase in circulating OPG from the mean baseline value of 52.5 pg/ml to the mean value of 75.7 pg/ml at evaluation was observed (Figure [1](#F1){ref-type="fig"}). All available samples were entered into this analysis but with variability in the number of cases throughout the various sampling points (*n* = 57--74). One reason was that several patients with CTCAE grade 3 diarrhea or other high-grade adverse treatment events were lost for further serum sampling when they were admitted at local hospitals. For other study patients, remaining serum lots could not be retrieved.

![Serum OPG levels during neoadjuvant therapy\
Using the single-parameter immunoassay, OPG was measured in serum sampled from patients at baseline (*n* = 74), post-NACT (*n* = 64), post-CRT (*n* = 61), and at evaluation of the neoadjuvant treatment (*n* = 57). For each sample group, where mean value is indicated by a line, distribution of values was different from baseline (\* *P* \< 0.01, \*\* *P* \< 0.0001; calculated by unpaired one-way analysis of variance).](oncotarget-07-34907-g001){#F1}

As seen from Table [2](#T2){ref-type="table"}, the baseline OPG measures (range 13.6--177 pg/ml; *n* = 74) demonstrated significant correlations with patients\' age as well as common markers of systemic inflammation, such as baseline erythrocyte sedimentation rate (ESR) and post-NACT neutrophil-to-lymphocyte ratio (NLR). Related to this, negative correlation with the serum albumin level and hence, positive correlation with the level of ionized calcium were seen. Moreover, at each sampling point during active therapy, correlation was found between the level of OPG and the actual monocyte count ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Correlation between age and serum OPG has also been reported by other investigators \[[@R21], [@R22]\], and further analyses were therefore conducted on age-adjusted OPG values.

###### Correlations between baseline serum osteoprotegerin levels and other patient factors

                                    *n* (%)    Correlation   *P*-value
  --------------------------------- ---------- ------------- -----------
  Age (years)                       74 (100)   0.30          0.009
  Body mass index (kg/m^2^)         73 (99)    −0.05         0.649
  Hemoglobin (g/dl)                 74 (100)   −0.14         0.244
  Thrombocytes (10^9^/l)            74 (100)   0.14          0.252
  Leukocytes (10^9^/l)              74 (100)   0.25          0.035
  Neutrophils (10^9^/l)             74 (100)   0.19          0.097
  Lymphocytes (10^9^/l)             72 (97)    0.16          0.173
  Monocytes (10^9^/l)               71 (96)    0.34          0.004
  NLR Baseline                      72 (97)    0.03          0.800
  NLR Post-NACT                     62 (84)    0.33          0.009
  Albumin (g/l)                     74 (100)   −0.25         0.032
  Ionized calcium (mmol/l)          72 (97)    0.24          0.042
  ESR (mm/h)                        67 (91)    0.26          0.033
  Carcinoembryonic antigen (μg/l)   74 (100)   0.12          0.315

Determined by Pearson product correlation.

Abbreviations: ESR, erythrocyte sedimentation rate; NACT, neoadjuvant chemotherapy; NLR, neutrophil-to-lymphocyte ratio.

Patient parameters and disease outcome {#s2_3}
--------------------------------------

When last censored, median follow-up time for the whole study population of 85 cases within the current report was 59 months (range 3--66). Three patients had experienced local recurrence as the first event of disease relapse. In addition, 28 patients had metastatic progression as the first event, with liver as the dominantly affected organ (16 cases) followed by lungs (eight cases) and other sites (four cases). Hence, PFS was chosen as the relevant long-term endpoint. As seen in Table [3](#T3){ref-type="table"}, univariate Cox regression analysis revealed significant association, reflected by hazard ratio (HR), between a PFS event and poor histologic (yp) tumor-node (TN) down-staging (ypT3--4: HR 4.05; ypN1--2: HR 3.83) and poor tumor regression grade (TRG) score (TRG 3--5: HR 2.61) in the surgical specimens from mainly T3--4 cases. Moreover, favorable PFS was associated with older age (HR 0.14), higher baseline hemoglobin (HR 0.04), less treatment toxicity (CTCAE grade 0--2 diarrhea: HR 0.37), and interestingly, dose reduction of oxaliplatin during CRT (HR 0.48) and a longer time span from CRT completion to surgery (HR 0.02). In contrast, both high baseline ESR (HR 1.85) and post-NACT NLR (HR 1.89) were associated with adverse PFS. And with reference to the correlations between baseline serum OPG measures and these inflammation markers (Table [2](#T2){ref-type="table"}), high OPG levels (age-adjusted) were also associated with unfavorable PFS (HR 3.33). In multivariate analysis, entering baseline variables with significant association with PFS, low hemoglobin remained associated with adverse PFS while OPG (HR 2.55; *P* = 0.051) failed to reach significance ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

###### Progression-free survival -- univariate analysis

                                                               *n* (%)    Median (range)      HR (95% CI)          *P*-value
  ----------------------------------------------- ------------ ---------- ------------------- -------------------- -----------
  Sex                                             Female       35 (41)                                             
                                                  Male         50 (59)                        0.98 (0.48--2.00)    0.957
  TN stage                                        T2           5 (6)                                               
                                                  T3           50 (59)                                             
                                                  T4           30 (35)                        1.71 (0.91--3.23)    0.095
                                                  N0           10 (12)                                             
                                                  N1           9 (11)                                              
                                                  N2           65(77)                         1.20 (0.68--2.10)    0.536
                                                  ND           1                                                   
  ypTN stage[a](#tfn_001){ref-type="table-fn"}    ypT0--2      43 (51)                                             
                                                  ypT3--4      41 (49)                        4.05 (1.80--9.13)    0.001
                                                  ND           1                                                   
                                                  ypN0         57 (67)                                             
                                                  ypN1--2      27 (33)                        3.83 (1.86--7.91)    0.000
                                                  ND           1                                                   
  TRG score[a](#tfn_001){ref-type="table-fn"}     TRG 1--2     60 (70)                                             
                                                  TRG 3--5     24 (30)                        2.61 (1.26--5.38)    0.010
                                                  ND           1                                                   
  CTCAE score[b](#tfn_002){ref-type="table-fn"}   CTCAE 0--2   52 (61)                        0.37 (0.16--0.87)    0.023
                                                  CTCAE 3      12 (14)                                             
                                                  ND           21 (25)                                             
  NACT                                            Full dose    77 (90)                                             
                                                  Reduction    8 (10)                         0.59 (0.14--2.48)    0.471
  Oxaliplatin during CRT                          Full dose    20 (24)                                             
                                                  Reduction    65 (76)                        0.48 (0.23--0.99)    0.048
  Capecitabine during CRT                         Full dose    28 (33)                                             
                                                  Reduction    57 (67)                        0.87 (0.42--1.81)    0.706
  Radiation                                       Full dose    80 (94)                                             
                                                  Reduction    5 (6)                          0.53 (0.07--3.90)    0.530
  Age (years)                                                  85 (100)   59 (30--73)         0.14 (0.03--0.71)    0.018
  Body mass index (kg/m^2^)                                    84 (99)    24.6 (17.9--34.8)   2.50 (0.17--37.5)    0.509
  Time from CRT completion to surgery (weeks)                  66 (78)    7.4 (4.4--10.4)     0.02 (0.00--0.41)    0.010
  Hemoglobin (g/dl)                                            85 (100)   13.9 (9.3--16.3)    0.04 (0.00--0.51)    0.013
  Thrombocytes (10^9^/l)                                       85 (100)   320 (182--990)      2.90 (0.89--9.43)    0.078
  Leukocytes (10^9^/l)                                         85 (100)   7.3 (4.0--16.2)     1.26 (0.34--4.65)    0.726
  Neutrophils (10^9^/l)                                        85 (100)   4.8 (2.3--12.8)     1.27 (0.47--3.44)    0.638
  Lymphocytes (10^9^/l)                                        83 (98)    1.8 (0.90--3.9)     0.74 (0.22--2.50)    0.622
  Monocytes (10^9^/l)                                          82 (96)    0.6 (0.2--1.4)      0.81 (0.31--2.11)    0.662
  Baseline NLR                                                 83 (98)    2.4 (1.2--9.3)      1.28 (0.56--2.91)    0.561
  Post-NACT NLR                                                70 (82)    1.4 (0.6--15.8)     1.89 (1.08--3.31)    0.025
  Albumin (g/l)                                                85 (100)   42 (25--48)         0.32 (0.01--17.4)    0.574
  Ionized calcium (mmol/l)                                     83 (98)    2.37 (2.22--2.76)   0.59 (0.00--11959)   0.916
  ESR (mm/h)                                                   76 (89)    14 (2--106)         1.85 (1.10--3.11)    0.021
  Carcinoembryonic antigen (μg/l)                              85 (100)   3 (0--122)          1.02 (0.90--1.16)    0.715
  Baseline OPG (pg/ml/year)                                    74 (87)    0.9 (0.2--2.6)      3.33 (1.24--8.94)    0.017
  Post-NACT OPG (pg/ml/year)                                   64 (75)    1.2 (0.3--4.6)      1.42 (0.61--3.29)    0.419
  Post-CRT OPG (pg/ml/year)                                    61 (72)    1.2 (0.4--4.0)      1.56 (0.63--3.91)    0.339
  Evaluation OPG (pg/ml/year)                                  57 (67)    1.3 (0.1--3.0)      0.80 (0.37--1.69)    0.552

One patient had disease progression in the pelvic cavity during neoadjuvant treatment and therefore proceeded to palliative surgery. As consequence, histologic tumor response data was missing, and the single case was omitted from these analyses.

Twenty-one patients had either baseline Common Terminology Criteria for Adverse Events (CTCAE) diarrhea scores \>0 or did not report maximum CTCAE grade diarrhea, and were therefore omitted from this analysis.

Other abbreviations: CI, confidence interval; CRT, chemoradiotherapy; ESR, erythrocyte sedimentation rate; HR, hazard ratio; NACT, neoadjuvant chemotherapy; ND, not determined; NLR, neutrophil-to-lymphocyte ratio; OPG, osteoprotegerin; TN, tumor-node; TRG, tumor regression grade; ypTN, histologic TN stage.

Changes in circulating OPG during neoadjuvant therapy {#s2_4}
-----------------------------------------------------

With reference to the observed population-based increase in circulating OPG throughout the course of neoadjuvant combined-modality therapy (Figure [1](#F1){ref-type="fig"}), we investigated whether alteration in the individual patient\'s serum OPG level at each of the sampling points (relative to the previous one) might reflect the contribution of the respective completed therapy component to overall outcome and tolerance. Firstly, for PFS, only the change at NACT completion (relative to baseline) was predictive with estimated 5-year PFS rate of 78% *versus* 48% when separating available cases (*n* = 58 for this particular analysis) with increase in the serum OPG level during NACT from those without (Figure [2](#F2){ref-type="fig"}), even though patients with and without increase were equally distributed with regard to ypTN status and TRG scores ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

![Serum OPG levels and PFS\
Patients were separated into cases with (solid line) or without (dashed line) increase in circulating OPG levels from baseline to completion of induction neoadjuvant chemotherapy, as measured by the single-parameter immunoassay. The difference between the two groups was significant (log-rank test; *P* = 0.009).](oncotarget-07-34907-g002){#F2}

Secondly, in this study population, pelvic CRT was the treatment modality that caused intestinal toxicity \[[@R14]\]. Since OPG does not show tumor-specific expression, its release into the circulation might, in susceptible individuals, reflect treatment-induced enteritis that clinically presents as diarrhea. To precisely define adverse events specifically associated with the therapy, patients reporting diarrhea at baseline (as presenting symptom of their disease) or with the maximum CTCAE score missing were omitted from this analysis. The remaining cases were categorized according to the maximum CTCAE score recorded during the neoadjuvant treatment. No patient reported higher than CTCAE grade 3 diarrhea. Hence, categories consisted of cases devoid of diarrhea (CTCAE grade 0) throughout the treatment course and cases reporting maximum CTCAE grade 1, 2, and 3 diarrhea, respectively. On comparison of the CTCAE grade 3 category (reflecting injury of grave severity that will trigger treatment adjustment and usually involves hospital admission) with CTCAE grades 0--2 (corresponding to no higher than moderate toxicity) grouped together, the change in serum OPG level during NACT was not found to be associated with adverse CTCAE grade diarrhea ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Of note, this specific analysis was compromised by the low number of serum samples from CTCAE grade 3 cases. Moreover, the neoadjuvant regimen was adjusted according to toxicity by reducing doses of or entirely discontinuing oxaliplatin, capecitabine, or radiotherapy in that order of priority, in accordance with the relative importance of the three therapeutic components. As a consequence (Table [3](#T3){ref-type="table"}), CTCAE grade 3 diarrhea was reported only by 19% of all cases (with known maximum score) within the current report, and 76% and 67% had dose reduction of oxaliplatin and capecitabine, respectively. In contrast, 94% of patients received the total prescribed radiation dose. Only five patients had a break during delivery (data not shown).

DISCUSSION {#s3}
==========

In this rectal cancer cohort with locally advanced tumors, elevated levels of systemic inflammation markers on commencement of neoadjuvant combined-modality therapy were associated with adverse PFS. On the contrary, the association between increase in circulating OPG following induction NACT and favorable outcome in patients given curatively intended sequential CRT, but with metastatic disease as the main adverse event, suggests that systemic anti-tumor effects may have been invoked by the combined-modality therapy in patients who achieved long-term disease control. One might hypothesize that OPG mediates or reflects immune effector priming by the induction NACT.

The study population within the current report revealed significant associations between adverse outcome and well-known unfavorable clinical parameters, such as poor histologic TN down-staging and tumor regression following the neoadjuvant therapy. In a similar fashion to our study, recent analysis of large retrospective series has indicated that a prolonged interval between completion of long-course neoadjuvant therapy and surgery may increase the likelihood of achieving excellent histologic tumor response \[[@R23]-[@R25]\]. The observation that patients who did not receive the full protocol-specified oxaliplatin dose during CRT had favorable PFS is in line with reports (though from retrospective analyses), where neutropenia from oxaliplatin-containing chemotherapy was associated with improved survival in metastatic colorectal and gastric cancer \[[@R26], [@R27]\]. In this context, improved tumor response has been related to strong oxaliplatin-DNA adduct formation in white blood cells \[[@R28]\]. Additionally, in agreement with our findings, previous studies have reported low hemoglobin and circulating lymphocytes being adverse prognostic factors in LARC patients given neoadjuvant therapy \[[@R29], [@R30]\]. The association between CTCAE grade 3 diarrhea and unfavorable PFS in our study is also in accordance with the recognition that an adverse event causing interruption in the radiation delivery is likely to have a negative influence on the probability of tumor control \[[@R4]\]. With all of this taken together, the current study population should be regarded as representative for LARC, and it is tempting to postulate that our descriptive data may reflect biologically significant mechanisms in outcome to combined-modality therapy in rectal cancer.

Interestingly, the TNF decoy receptor OPG showed apparently contradictory biological behavior. On the one hand, high baseline serum OPG levels were associated with unfavorable PFS, though it just failed to reach significance in multivariate analysis. On the other hand, patients with a rise in serum OPG measures during the neoadjuvant treatment course had better PFS than those without.

On binding to RANK, RANKL-induced signaling results in osteoclast activation, which is central for bone homeostasis. In this regulatory loop, OPG (literally, protector of bone) acts as a soluble receptor that deprives RANK of its ligand \[[@R17], [@R18]\]. The correlations observed in the present study between high baseline OPG levels and serological markers that in clinical practice frequently are deranged in cancer patients with poor prognosis, including elevated ionizing calcium, may suggest that high *de novo* circulating OPG reflects a rescue response to the high osteoclast activity that is associated with disease of grave severity and not an adverse disease mechanism in itself. Alternatively, elevated serum OPG at baseline may mirror elevated OPG expression in primary CRC tumors with high propensity to metastasize, which has been explained by autocrine OPG-dependent prevention of tumor cell apoptosis via inhibitory binding of the TNF-related apoptosis-inducing ligand \[[@R31], [@R32]\].

Moreover, the level of circulating OPG increased throughout the neoadjuvant treatment course and correlated with the actual monocyte count at each sampling point. Since OPG is expressed by monocyte-derived dendritic cells \[[@R15]\], these observations suggest that the study treatment may have caused dendritic cell activation. When separating study patients into cases who did or did not experience a rise in serum OPG levels during NACT, significantly better PFS was found for the former group, even though patients with and without increase were equally distributed among cases with favorable and unfavorable histologic ypTN and TRG outcomes in the surgical specimens. This finding indicates that the serum OPG response may add independent prognostic and indeed, biological information to current routine practice.

Importantly, we could not exclude the possibility that alterations in serum content of OPG reflected deleterious normal tissue effects. With the particular study design, the pelvic CRT caused intestinal toxicity \[[@R14]\], and the normal bowel might therefore contribute to alterations in circulating levels of OPG. Already a decade ago, a preclinical study using a mouse model demonstrated that OPG-dependent quenching of the RANKL-RANK interaction inhibited the severity of T lymphocyte-mediated bowel inflammation by decreasing the number of local, colonic dendritic cells \[[@R33]\]. However, no correlations were found between NACT-induced alterations in serum OPG and diarrhea scores. Essentially, the study displayed low incidence of CTCAE grade 3 diarrhea, probably reflecting the precaution criteria in the study protocol. The safety concerns may have precluded the quest for circulating markers of treatment toxicity.

Finally, in this patient cohort, we recently observed that the short-course induction NACT in patients with favorable PFS caused a strong increase in circulating carbonic anhydrase IX \[[@R34]\]. This tumor-specific enzyme is induced by tumor hypoxia and causes microenvironmental acidification, which is recognized as a main mechanism in resistance to cytotoxic therapy and metastatic progression \[[@R35]-[@R37]\]. Our data was interpreted as NACT-specific eradication of hypoxic tumor components, resulting in enhancement of CRT efficacy \[[@R34]\]. Given the parallel increase in circulating OPG levels associated with favorable outcome, it is tempting to speculate that the induction NACT also caused immune effector priming of the tumor, resulting in enhanced systemic anti-tumor immunity from the sequential CRT. The integral biology of local tumor microenvironmental and systemic immune responses will probably position itself within clinical radiation oncology practice in the near future \[[@R38]\].

MATERIALS AND METHODS {#s4}
=====================

Patients, treatment, and serum sampling for LARC-RRP {#s4_1}
----------------------------------------------------

The study protocol ([ClinicalTrials.gov](https://ClinicalTrials.gov) NCT00278694) was approved by the Institutional Review Board and Regional Committee for Medical and Health Research Ethics and was in accordance with the Helsinki Declaration. Written informed consent was required for participation. The study population of 85 cases within the current report was enrolled from October 5, 2005 through March 3, 2010. Patient eligibility criteria, evaluation procedures, and review procedures of follow-up have been described previously \[[@R39]\]. The neoadjuvant treatment protocol consisted of two cycles of NACT (the Nordic FLOX regimen: oxaliplatin 85 mg/m^2^ on day 1 and bolus fluorouracil 500 mg/m^2^ and folinic acid 100 mg on days 1 and 2 every second week) followed by CRT. Radiation was delivered in 2-Gy fractions five days per week over a 5-week period, with concomitant weekly oxaliplatin 50 mg/m^2^ and capecitabine 825 mg/m^2^ twice daily on days of radiotherapy. Formal recording of adverse events according to CTCAE version 3.0 was performed at baseline, at completion of NACT (post-NACT) and CRT (post-CRT), and at the time of treatment evaluation four weeks after its completion. Surgery was planned 6--8 weeks after completion of the neoadjuvant treatment. In accordance with national guidelines, patients did not proceed to further therapy. Study serum samples were collected at baseline, post-NACT, post-CRT, and at the time of treatment evaluation, and were stored at −80°C until analysis. Routine blood tests were done within the standard patient follow-up.

Antibody array technology and data analysis {#s4_2}
-------------------------------------------

Serum samples (baseline, *n* = 66; post-NACT, *n* = 61; post-CRT, *n* = 59; evaluation, *n* = 55) were analyzed with a high-density antibody array (AAH-BLG-1; RayBiotech, Inc., Norcross, GA, USA) at the Genomics Core Facility, Oslo University Hospital. Serum proteins were biotinylated and added onto glass slides pre-printed with 507 capture antibodies. Bound proteins (in duplicates) were detected with a streptavidin-conjugated fluorescent dye, HiLytePlus™ 555 (60672-Plus555; AnaSpec, Inc., Freemont, CA, USA), and the arrays were scanned for fluorescence using the Agilent scanner G2505C (Agilent Technologies, Santa Clara, CA, USA). GenePix version 6.0 (Molecular Devices Corporation, Union City, CA, USA) was used to convert array image spots to numerical values. The array data is available in the Gene Expression Omnibus repository by accession number GSE65622.

Following data processing as detailed in the Supplementary information within the deposited data, the data was transformed to natural logarithms, and changes in circulating proteins during the neoadjuvant treatment course were determined with the SAM software version 5.0 employing paired analysis and a false discovery rate cut-off of 10% \[[@R40]\]. Herein, each protein that within the study population was significantly altered during the neoadjuvant treatment received a score on the basis of its change relative to the standard deviation of repeat measurements. The software handles any missing data by imputation using the *K*-nearest neighbor method \[[@R40]\].

Single-parameter analysis of OPG {#s4_3}
--------------------------------

Serum samples (baseline, *n* = 74; post-NACT, *n* = 64; post-CRT, *n* = 61; evaluation, *n* = 57) were analyzed for OPG levels using a single-parameter immunoassay (ELH-OPG; RayBiotech, Inc.), according to the instructions manual. Before analysis, serum samples were diluted 1:4. All samples were analyzed in duplicates.

Study endpoints {#s4_4}
---------------

The clinical endpoints were treatment toxicities (CTCAE scores) during neoadjuvant therapy, histologic tumor response, and PFS. Follow-up data was censored on August 8, 2013. The resected tumor specimens were histologically evaluated for treatment response according to standard staging (ypTN; TNM version 5). In this patient population of locally advanced tumors (mainly T3--4 cases), ypT0--2 results were considered as good response and correspondingly, ypT3--4 results were regarded as poor tumor shrinkage. Moreover, histologic tumor response was graded within one of five TRG categories, spanning from the absence of residual tumor cells in the resected specimen (pathologic complete response; TRG 1) to the lack of morphologic signs of tissue response to treatment (TRG 5) \[[@R41]\]. Of note, when responding to neoadjuvant treatment, LARC frequently shows fragmentation into microscopic residual disease \[[@R42]\]. Consequently, it is rational to group TRG 2 together with TRG 1 as good histologic regression and correspondingly, the range of TRG 3--5 scores as poor response.

Statistical analysis {#s4_5}
--------------------

Analyses were preformed using IBM SPSS Statistics for Windows version 23.0 or GraphPad Prism version 6.0h. Correlations between continuous data were determined by Pearson product correlation analysis after transformation to natural logarithms for symmetric distribution. Continuous data was described with either mean and standard deviation or median and range, and groups were compared using one-way analysis of variance with Holm-Sidak\'s test for multiple comparisons. Categorical data was compared using Chi-square test or Fisher\'s exact test when small numbers were involved. Estimated 5-year PFS was calculated from the time of study enrolment to the date of recurrent disease (diagnosis of local recurrence or distant metastasis), death of any cause, or end of follow-up (five years after the date of surgery), whichever came first. Crude differences in survival were assessed by the log-rank test and visualized by the Kaplan-Meier method. Associations between selected variables and PFS were modeled with univariate and multivariate Cox regression analysis. The results were expressed as HR with 95% confidence interval. All tests were two-sided. *P*-values less than 0.05 were considered statistically significant.
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